ISRCTN77353795已完成未知
A randomised trial of epirubicin versus mitomycin C at the time of first recurrence in superficial bladder cancer
Medical Research Council (MRC) (UK)0 个研究点目标入组 800 人开始时间: 2001年2月28日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Newly-diagnosed superficial carcinoma of bladder suitable for complete endoscopic resection, limited to the bladder
- •2. World Health Organisation (WHO) status zero to two
- •3. Expected survival at least three years
- •4. No history of other malignant tumours, except non-melanomatous skin tumours, or carcinoma in-situ (CIN)
- •5. No untreated urinary tract infection (UTI)
排除标准
- •Not provided at time of registration
研究者
相似试验
已完成
不适用
A randomized phase II trial comparing epirubicin, cisplatin, and capecitabine versus the combination of epirubicin, cisplatin, and capecitabine with pravastatin in patients with irresectable or metastatic gastric carcinomaCancerISRCTN23062732Erasmus Medical Center, Department of Medical Oncology (Netherlands)43
进行中（未招募）
1 期
Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine and Herceptin in Early Breast Cancerearly HER-2 breast cancerEUCTR2004-002030-19-ATAUSTRIAN BREAST CANCER STUDY GROUP536
已完成
不适用
A randomised trial of epirubicin and cyclophosphamide versus epirubicin and paclitaxel in the treatment of women with metastatic breast cancerCancerBreast cancerISRCTN75147488Medical Research Council (MRC) (UK)700
已完成
不适用
A randomised trial comparing epirubicin, cisplatin and protracted venous infusion (PVI) 5-Fluorouracil (5FU) (ECF) to 5FU, Etoposide Leucovorin (FELU) in patients with inoperable or metastatic biliary cancerBiliary TractBiliaryCancerISRCTN73941125The Royal Marsden NHS Foundation Trust (UK)
进行中（未招募）
1 期
Randomized trial of sequential epirubicin and docetaxel against docetaxel in patients with early operable breast cancer. - READ TOP2AWomen with operable breast cancer and increased risk of recurrenceEUCTR2007-003126-15-DKDBCG1,932